Growth Hormone / side effects and safety / Last reviewed 2026-04-04

Hexarelin Side Effects: Safety Signals and Warnings

Hexarelin safety concerns are compound-specific. The main listed side effects are Flushing, Transient cortisol elevation, and Increased appetite. The main warning signals are Not approved for clinical use, Tachyphylaxis occurs with continuous use - intermittent dosing recommended, and Transient increases in cortisol and prolactin may be clinically relevant in susceptible individuals.

Read the full Hexarelin guide Browse answer pages

Direct Answer

Hexarelin has Phase 2 human data on GH release and cardioprotective effects, but its side-effect profile - significant cortisol and prolactin elevation, rapid desensitization - makes it a poor practical starting point compared to ipamorelin. The cardiac GHS-R1a data is scientifically interesting, but the compound's limitations are real. Ipamorelin is a cleaner choice for GH secretagogue research; hexarelin is mainly useful for studying GHRP receptor pharmacology specifically.

Evidence grade
Level C
Research status
Phase 2
Category
Growth Hormone
Best for
GHRP receptor pharmacology, cardioprotective GH secretagogue research

Reported Side Effects

Warnings

Known or Plausible Interactions

Regulatory Context

Not FDA approved. Available as a research chemical. Banned by WADA in competitive sports.

Evidence Snapshot

Evidence gradeLevel C
Research statusPhase 2
Best supported outcomesGrowth Hormone Release (Level B), Cortisol and Prolactin Elevation (Level B), and Cardioprotection (Level C)
Primary citation count2
Last reviewed2026-04-04

Related Guides

How to Cite This Page

ExaminePeptides. "Hexarelin Side Effects: Safety Signals and Warnings." Last reviewed 2026-04-04. https://examinepeptides.com/answers/hexarelin-side-effects-safety/

This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.